TMCnet News

Liquid Biopsy Market by Cancer Type, Circulating Biomarkers, Product, End Use - Expected to Reach USD 1.66 Billion by 2021 - Research and Markets
[July 27, 2016]

Liquid Biopsy Market by Cancer Type, Circulating Biomarkers, Product, End Use - Expected to Reach USD 1.66 Billion by 2021 - Research and Markets


Research and Markets has announced the addition of the "Liquid Biopsy Market by Cancer Type, Circulating Biomarkers, Product, End Use - Forecast to 2021" report to their offering.

The liquid biopsy market is expected to reach USD 1.66 billion by 2021 from USD 0.58 billion in 2016, growing at a CAGR of 23.4% during the forecast period of 2016 to 2021. Liquid biopsy is a non-invasive alternative to invasive solid tumor biopsies; it detects biomarkers from primary tumors and from metastatic sites to ascertain genetic information about tumors.

Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers (melanoma, bladder cancer, and ovarian cancer).

Based on circulating biomarkers, the liquid biopsy market is segmented into circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other biomarkers (circulating RNA and protein). The circulating tumor cells segment is expected to account for te largest share of the global liquid biopsy market in 2016, followed by the circulating tumor DNA segment.



Based on end user, the liquid biopsy market is classified into hospital/physician laboratories, reference laboratories, academic and research centers and other end users.

A number of factors, such as technological advancements, increasing number of new cancer cases, benefits of liquid biopsy over solid tumor biopsy, availability of funding, and growing awareness about liquid biopsy through conferences and government initiatives are driving the growth of the liquid biopsy market. However, the unclear regulatory and reimbursement scenario is one of the major factors restraining the growth of this market.


Companies Mentioned:

  • Bio-Rad Laboratories Inc.
  • Biocept, Inc.
  • F. Hoffmann-La Roche AG
  • Fraunhofer (News - Alert)-Gesellschaft
  • Guardant Health Inc.
  • Janssen Diagnostics, LLC.
  • MDX Health SA
  • Myriad Genetics
  • Qiagen
  • Tr0vagene Inc.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Insights

7 Liquid Biopsy Market, By Cancer Type

8 Liquid Biopsy Market, By Circulating Biomarker

9 Liquid Biopsy Market, By Products and Services

10 Liquid Biopsy Market, By End User

11 Liquid Biopsy Market, By Region

12 Competitive Landscape

13 Company Profiles

For more information visit http://www.researchandmarkets.com/research/xc4mmw/liquid_biopsy


[ Back To TMCnet.com's Homepage ]